Some items on our site have recently moved. Visit our News Hub for selected articles, special reports, podcasts and other resources.
AbbVie, Allergan well-positioned for unconditional clearance in Brazil
22 October 2019 12:41 by Ana Paula Candil
AbbVie’s $63 million merger with Allergan is well-positioned for unconditional antitrust clearance in Brazil, MLex has learned.
Approval by the Administrative Council for Economic Defense, or CADE, is expected to be announced soon.
AbbVie and Allergan submitted merger paperwork on Aug. 22, but amended their notification form, pushing the review deadline to Nov. 14.
AbbVie and Allergan are listed on the New York Stock Exchange.
Related Articles
-
China’s semiconductor industry is grappling with the implications of stricter export controls imposed by the US -
Meta Platforms’ acceptance of a UK order to unwind its Giphy deal this week puts an end to more than two years of wrangling -
Norsk Hydro’s Alumetal deal, EU heightened vigilance about large companies snapping up smaller, innovative competitors.